It has been also shown that TH17 responses alleviate cancer pathogenesis and improve survival in CLL cases.47,48 We previously reported that ibrutinib enhances IL-17 responses, which modulate antigen presentation and DC functions.17 Similarly, in our present study, we found that ibrutinib treatment was associated with a significant increase in IL-17 production, which could be responsible for enhancing T cell-mediated antitumour responses. The gene discussed is IL17A; the disease is B-cell chronic lymphocytic leukemia.